Results 1 to 10 of about 17 (16)

Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2

Качественная клиническая практика, 2019
Fixed antidiabetic drugs’ combinations have aim to improve of Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control of fasting and prandial glucose levels, contained ...
S. К. Zyryanov, I. N. Dyakov
doaj   +2 more sources

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base

Качественная клиническая практика, 2021
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Agonists of receptors for glucagon like peptide-1 (aGLP-1) are one of the modern option for glycemia control in DM Type 2 ...
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists

Качественная клиническая практика, 2022
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are one of the modern options for glycemia control in DM Type 2 and ...
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus

Качественная клиническая практика, 2021
Insulin glargine 100 U/ml (iGla) is gradually giving way to a fixed combination of insulin glargine 100 U/ml+ lixisenatide (iGlaLixi) — an effective and safe drug for Diabetes Mellitus Type 2 (DM2T) control.
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2

Качественная клиническая практика, 2020
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM ...
S. V. Nedogoda, A. S. Salasyuk, I. N. Barikina, V. O. Smirnova, M. Yu. Frolov   +4 more
doaj   +1 more source

Economic evaluation of insulin therapy intensification for effective and safe control of diabetes mellitus type 2

Качественная клиническая практика, 2019
Insulin therapy is one of the effective methods of effective control of diabetes mellitus type 2 (T2DM) which can manage resistance to insulin. Insulin’s analogs have advantages in compare with human insulins in frames of safety (less amount of ...
A. S. Kolbin, A. A. Kurilev, Yu. E. Balikina, M. A. Proskurin, O. I. Karpov   +4 more
doaj   +1 more source

Economic perspectives for effective control of diabetes mellitus type 2 with fixed combination of basal insulin analog and GLP-1 agonist

Качественная клиническая практика, 2019
Fixed antidiabetic drugs’ combinations have aim to improve Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control fasting and prandial glucose levels, contained insulin ...
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2

Качественная клиническая практика, 2018
Usage of glucagon like peptide-1 receptors’ agonists (aGLP-1) is a new step in the treatment of Diabetes Mellitus Type 2 (DM 2). General attractive effects are positive effect on bodyweight, lower risk of hypoglycemia, compliance and possibility of ...
A. S. Kolbin, A. A. Mosikyan, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, W. Zhao   +5 more
doaj  

[Synergistic effects of GABA and hypoglycemic drugs]. [PDF]

Probl Endokrinol (Mosk), 2023
Tyurenkov IN, Faibisovich TI, Bakulin DA.   +2 more
europepmc   +1 more source

[Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016-2020 years dynamics]. [PDF]

Probl Endokrinol (Mosk), 2023
Kurkin DV, Makarova EV, Krysanov IS, Bakulin DA, Robertus AI, Ivanova OV, Kolosov YA, Kudrin RA.   +7 more
europepmc   +1 more source